SOPH and MYGN Related Headlines
Go Back- Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
- Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
- Myriad Genetics partners with SOPHiA GENETICS on liquid biopsy test
- Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
- Myriad Genetics and SOPHiA GENETICS to DevelopĀ an Innovative Companion Diagnostic Offering in Liquid Biopsy
SOPH and MYGN Related Press Releases
Go Back- Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
- Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
- Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
- Myriad Genetics and SOPHiA GENETICS to DevelopĀ an Innovative Companion Diagnostic Offering in Liquid Biopsy

